Comparative Pharmacology
Head-to-head clinical analysis: DYCLOPRO versus JUNIOR STRENGTH IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCLOPRO versus JUNIOR STRENGTH IBUPROFEN.
DYCLOPRO vs JUNIOR STRENGTH IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
50 mg intravenously every 8 hours
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Category C
Category D/X
NSAID
NSAID